Update on Dopamine Agonists in Parkinson's Disease: “Beyond Bromocriptine”

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques

• Publication date

  1987-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1017/S031716710003794XPMID 3315148
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of B-HT 920 and B-HT 933 on dopamine and noradrenaline autoreceptors in the rat brain.

  2009cited by this paper
• Therapeutic efficacy of a partial dopamine agonist in drug-free parkinsonian patients

  2005cited by this paper
• Mesulergine and bromocriptine in long-term treatment of advanced parkinsonism

  2005cited by this paper
• Adjuvant treatment of parkinson's disease with dopamine agonists: Open trial with bromocriptine and CU 32-085

  2004cited by this paper
• Dopamine receptor agonistic and antagonistic effects of 3-PPP enantiomers

  2004cited by this paper
• Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism

  2004cited by this paper
• Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP

  2004cited by this paper
• Transdihydrolisuride in Parkinsonism

  1987cited by this paper
• Recognizing neurotoxic disease

  1987cited by this paper
• Effect of ciladopa on Parkinson's disease: a preliminary report.

  1987cited by this paper
• Parallel double-blind study of pergolide in Parkinson's disease.

  1987cited by this paper
• Pergolide mesylate: four years experience in Parkinson's disease.

  1987cited by this paper
• Lisuride in parkinson's disease: naive and long-term treatment

  1986cited by this paper
• Evaluation of ciladopa hydrochloride as a potential anti-Parkinson drug.

  1986cited by this paper
• Individual manifestations of Parkinson's disease after ten or more years of levodopa

  1986cited by this paper
• Pharmacological profile of the abeorphine 201-678, a potent orally active and long lasting dopamine agonist.

  1986cited by this paper
• Bromocriptine, selective D2 dopamine receptor agonists and D1 dopaminergic tone

  1986cited by this paper
• The antiparkinson action of bromocriptine in combination with levodopa

  1986cited by this paper
• Efficacy of pergolide and mesulergine.

  1986cited by this paper
• Mesulergine (CU 32-085) in the treatment of Parkinson's disease.

  1986cited by this paper
• Alterations in motor behaviour produced by the isomers of 3-PPP in the MPTP-treated marmoset.

  1986cited by this paper
• Therapeutic effect of lisuride in advanced Parkinson's disease.

  1986cited by this paper
• Long-term efficacy of pergolide in patients with Parkinson's disease.

  1986cited by this paper
• Pharmacological profiles of three new, potent and selective dopamine receptor agonists: N-0434, N-0437 and N-0734.

  1986cited by this paper
• Mesulergine in early Parkinson's disease: a double blind controlled trial.

  1986cited by this paper
• The dopamine autoreceptor agonist B-HT 920 stimulates denervated postsynaptic brain dopamine receptors in rodent and primate models of Parkinson's disease: a novel approach to treatment.

  1986cited by this paper
• Double‐blind assessment of potential pergolide‐induced cardiotoxicity

  1986cited by this paper
• Therapeutic experience with transdihydrolisuride in Huntington's disease

  1986cited by this paper
• Clinical trial for Parkinson's disease?

  1985cited by this paper
• Initial treatment of parkinsonism with 8‐alpha‐amino‐ergoline

  1985cited by this paper
• (+)-4-Propyl-9-hydroxynaphthoxazine (PHNO), a new dopaminomimetic, in treatment of parkinsonism.

  1985cited by this paper
• Pergolide mesylate

  1985cited by this paper
• A possible molecular mechanism for the antiparkinsonian action of bromocriptine in combination with levodopa

  1985cited by this paper
• Lisuride in dystonia

  1985cited by this paper
• An electrophysiological analysis of the actions of the 3-PPP enantiomers on the nigrostriatal dopamine system

  1985cited by this paper
• Placebo‐controlled study of mesulergine in Parkinson's disease

  1985cited by this paper
• Mesulergine (CU32‐085) in the treatment of Parkinson's disease

  1985cited by this paper
• Parkinson's disease

  1985cited by this paper
• Double‐blind trial of pergolide for Parkinson's disease

  1985cited by this paper
• Long‐term study of pergolide in Parkinson's disease

  1985cited by this paper
• Chronic agonist therapy for Parkinson's disease

  1985cited by this paper
• Long‐term experience with pergolide therapy of advanced parkinsonism

  1985cited by this paper
• Lisuride treatment of focal dystonias

  1985cited by this paper
• The pharmacology of mesulergine.

  1985cited by this paper
• Pergolide therapy in Parkinson's disease: a double-blind, placebo-controlled study.

  1985cited by this paper
• Mesulergine treatment of parkinsons disease an 18 month follow up

  1984cited by this paper
• Low‐dose CU 32‐085 (Mesulergine) in previously untreated Parkinson? disease

  1984cited by this paper
• Glial and neuronal Na+‐K+ pump in epilepsy

  1984cited by this paper
• Bromocriptine and lisuride in Parkinson's disease.

  1984cited by this paper
• Use of ergot derivative lisuride in Parkinson's disease.

  1984cited by this paper
• N-0434, A very potent and specific new D-2 dopamine receptor agonist.

  1984cited by this paper
• Pergolide in the treatment of Parkinson's disease

  1984cited by this paper
• Long‐term treatment with pergolide

  1984cited by this paper
• Pergolide and lisuride in advanced Parkinson's disease.

  1984cited by this paper
• (+)- and (-)-3-PPP exhibit different intrinsic activity at striatal dopamine autoreceptors controlling dopamine synthesis.

  1984cited by this paper
• The History and Pharmacology of Dopamine Agonists

  1984cited by this paper
• Pharmacological and Biochemical Evidence for the Existence of Two Categories of Dopamine Receptor

  1984cited by this paper
• TREATMENT OF PARKINSONʼS DISEASE WITH A DOPAMINE PARTIAL AGONIST

  1984cited by this paper
• Treatment of Parkinson's disease with 8‐alpha‐amino‐ergoline, CU 32–085

  1983cited by this paper
• Lisuride in the treatment of parkinsonism.

  1983cited by this paper
• Comparison of pergolide and bromocriptine therapy in parkinsonism

  1983cited by this paper
• Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease.

  1983cited by this paper
• Bromocriptine and lisuride in Parkinson disease

  1983cited by this paper
• Inclusion body myositis (IBM)

  1983cited by this paper
• Cortical Reflex Myoclonus Responds to Intravenous Lisuride

  1983cited by this paper
• Mesulergine and its 1,20-N,N-bidemethylated metabolite interact directly with D1- and D2-receptors.

  1983cited by this paper
• The effects of pergolide on the cardiovascular system of 40 patients with Parkinson's disease.

  1983cited by this paper
• Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy

  1983cited by this paper
• Dopamine agonists in the treatment of Parkinson's disease.

  1983cited by this paper
• Pergolide in late‐stage Parkinson disease

  1982cited by this paper
• Beneficial effects of lisuride in Meige disease

  1982cited by this paper
• Pergolide mesylate and idiopathic Parkinson disease

  1982cited by this paper
• Lisuride versus bromocriptine treatment in Parkinson disease

  1982cited by this paper
• Evidence that LY-141865 specifically stimulates the D-2 dopamine receptor

  1981cited by this paper
• Brain neurotransmitter receptors in Parkinson's disease

  1981cited by this paper
• 3-PPP, a new centrally acting DA-receptor agonist with selectivity for autoreceptors.

  1981cited by this paper
• Treatment of advanced Parkinson disease with pergolide

  1981cited by this paper
• Lisuride combined with levodopa in advanced Parkinson disease

  1981cited by this paper
• Activity of two new potent dopaminergic agonists at the striatal and anterior pituitary levels.

  1980cited by this paper
• Lisuride in the treatment of Parkinsonism

  1980cited by this paper
• The central effects of a novel dopamine agonist.

  1978cited by this paper
• Bromocriptine‐induced behavioral hypersensitivity

  1978cited by this paper
• Levodopa‐Induced dopamine receptor hypersensitivity

  1977cited by this paper
• Experiences with a new ergoline (CF 25–397) in parkinsonism

  1977cited by this paper
• Effect of lisuride and other ergot derivatives on monoaminergic mechanisms in rat brain.

  1977cited by this paper
• Treatment of Parkinson's disease with aporphines. Possible role of growth hormone.

  1976cited by this paper
• Amphetamine-induced dopaminergic hypersensitivity in guinea pigs. Implications in psychosis and human movement disorders.

  1975cited by this paper
• INCREASE IN FRACTURE OF THE FEMUR IN THE ELDERLY

  1975cited by this paper
• Injected apomorphine and orally administered levodopa in Parkinsonism.

  1972cited by this paper
• Evidence for a new type of dopamine receptor stimulating agent

  1971cited by this paper
• Apomorphine in Parkinson's disease.

  1951cited by this paper

• Interaction of the preferential D3 agonist (+)PHNO with dopamine D3-D2 receptor heterodimers and diverse classes of monoamine receptors: Relevance for PET imaging.

  2022cites this paper
• Tremulous jaw movements induced by the acetylcholinesterase inhibitor tacrine: effects of antiparkinsonian drugs.

  1997cites this paper
• Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen.

  1997cites this paper
• Dopamine agonists facilitate footshock-elicited locomotion in rats, and suppress lever-press responding for food

  1995cites this paper
• Considerations on the recognition of the D1 receptor by agonists

  1993cites this paper
• Comparison of methods to estimate the free energy of solvation:Importance in the modulation of the affinity of 3‐benzazepines for the D1receptor

  1993cites this paper
• [Patients with Parkinson disease: functional analysis of dopamine receptors by bromocriptine- thyrotropin-releasing hormone test].

  1991cites this paper
• Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.

  1991cites this paper
• Selegiline and the Treatment of Parkinson's Disease: How patients can benefit from drug therapy.

  1991cites this paper
• Selegiline and the Treatment of Parkinson's Disease: How patients can benefit from drug therapy.

  1991cites this paper
• Experiences with Sinemet CR in the Paracelsus-Elena-Klinik.

  1989cites this paper
• Animal models of parkinsonism using selective neurotoxins: clinical and basic implications.

  1989cites this paper
• Parkinson's disease: recent advances in therapy.

  1988cites this paper